← All trials
NCT05817812
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2023
- Primary completion
- Feb 28, 2026
- Completion date
- Feb 28, 2026
- First posted
- Apr 18, 2023
- Last posted
- Dec 8, 2023
- Enrollment
- 90
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Swedish Orphan BiovitrumLead sponsor
- Swedish Orphan BiovitrumStudy director
- Syneos HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.